Mitsubishi Tanabe rationalises manufacturing
This article was originally published in Scrip
Japan's Mitsubishi Tanabe Pharma(MTP) is to merge its wholly owned production subsidiaries MP-Technopharma and Tanabe Seiyaku Yamaguchi on October 1st. The surviving entity will be Osaka-based MP Technopharma, which will employ around 800 people, although the plant run by the former Tanabe operation will continue to operate. The move, which will have only a minor financial impact, forms part of rationalisation steps following the October 2007 merger of Mitsubishi Pharma and Tanabe to form MTP, which said that it is considering the further restructuring of its manufacturing activities.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.